MARKET

ICPT

ICPT

Intercept
NASDAQ

Real-time Quotes | Nasdaq Last Sale

39.09
-0.56
-1.41%
After Hours: 39.00 -0.09 -0.23% 17:39 09/23 EDT
OPEN
39.90
PREV CLOSE
39.65
HIGH
40.41
LOW
38.96
VOLUME
557.02K
TURNOVER
--
52 WEEK HIGH
125.00
52 WEEK LOW
38.96
MARKET CAP
1.29B
P/E (TTM)
-3.7724
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
SPI, JEF, PEAK and ICPT among after-hours movers
Gainers: [[SPI]] +58.3%. [[MCHX]] +16.1%. [[JEF]] +8.9%. [[PRVB]] +8.8%. [[DPW]] +3.5%.Losers: [[WNC]] -3.5%. [[PEAK]] -3.3%. [[ICPT]] -2.8%. [[NNOX]] -2.4%. [[BEKE]] -2.2%.
Seekingalpha · 4h ago
The Daily Biotech Pulse: Coronavirus Vaccine Updates From J&J & MediciNova, Australian Regulatory Nod For GW Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22)
Benzinga · 13h ago
The Daily Biotech Pulse: Legal Relief For Evolus, Fulgent to Join S&P SmallCap 600, AIM ImmunoTech's Positive Cancer Drug Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 21)
Benzinga · 1d ago
Analyst Report: Intercept Pharmaceuticals, Inc.
Find the latest Intercept Pharmaceuticals, Inc. (ICPT) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance
Morningstar Research · 09/10 23:34
Intercept (ICPT) Down 16.2% Since Last Earnings Report: Can It Rebound?
Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/09 15:30
Intercept's (ICPT) Stock Rises After Layoff Announcement
Intercept (ICPT) plans to lay off its workforce to save costs and streamline operations.
Zacks · 09/03 14:34
Intercept to Present at September Investor Conference
NEW YORK, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Mark Pruzanski, M.D., President and Chief
GlobeNewswire · 09/03 13:00
Intercept Pharmaceuticals Will Lay Off a Quarter of Its Staff as NASH Dream Fades
The company was once the front-runner in the race to develop a treatment for NASH, a newly defined liver disease
Barrons.com · 09/02 15:20
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ICPT. Analyze the recent business situations of Intercept through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 24 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ICPT stock price target is 67.68 with a high estimate of 140.00 and a low estimate of 46.00.
EPS
Institutional Holdings
Institutions: 309
Institutional Holdings: 28.32M
% Owned: 85.85%
Shares Outstanding: 32.98M
TypeInstitutionsShares
Increased
69
1.63M
New
65
1.30M
Decreased
52
1.39M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.78%
Pharmaceuticals & Medical Research
-1.14%
Key Executives
Chairman/Director
Paolo Fundaro
President/Chief Executive Officer/Director
Mark Pruzanski
Chief Financial Officer/Treasurer
Sandip Kapadia
Corporate Executive
Lisa Bright
Corporate Executive
Richard Kim
Chief Operating Officer
Jerome Durso
Chief Human Resource Officer
David Ford
Executive Vice President
Christian Weyer
Senior Vice President
Gail Cawkwell
General Counsel/Secretary
Ryan Sullivan
Vice President/Director of Investor Relations
Lisa DeFrancesco
Other
Jason Campagna
Lead Director/Independent Director
Gino Santini
Independent Director
Srinivas Akkaraju
Independent Director
Luca Benatti
Independent Director
Daniel Bradbury
Independent Director
Keith Gottesdiener
Independent Director
Nancy Miller-Rich
Independent Director
Glenn Sblendorio
Independent Director
Daniel Welch
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ICPT
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Intercept Pharmaceuticals Inc stock information, including NASDAQ:ICPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ICPT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ICPT stock methods without spending real money on the virtual paper trading platform.